Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are unable to identify an acceptable unrelated HLA matched donor through the registries in a timely manner. Another option is haploidentical transplant using a partially matched family member donor.
Although haploidentical transplant has proven curative in many patients, this procedure has been hindered by significant complications, primarily regimen-related toxicity including graft versus host disease (GVHD) and infection due to delayed immune reconstitution. These can, in part, be due to certain white blood cells in the graft called T cells. GVHD happens when the donor T cells recognize the body tissues of the patient (the host) are different and attack these cells. Although too many T cells increase the possibility of GVHD, too few may cause the recipient's immune system to reconstitute slowly or the graft to fail to grow, leaving the patient at high-risk for significant infection.
This research project will investigate the use of particular pre-transplant conditioning regimen (chemotherapy, antibodies and total body irradiation) followed by a stem cell infusion from a "mismatched" family member donor. Once these stem cells are obtained they will be highly purified in an effort to remove T cells using the investigational CliniMACS stem cell selection device. The primary goal of this study will be to determine the rate of neutrophil and platelet engraftment, as well as the degree and rate of immune reconstitution in the first 100 days posttransplant for patients who receive this study treatment. Researchers will also study ways to decrease complications that may occur with a transplant from a genetically mismatched family donor.
Przegląd badań
Status
Warunki
Szczegółowy opis
Secondary outcome evaluations for this clinical study include the following:
- To estimate overall survival, disease free survival and event free survival for these patients
- To estimate the incidence of grade 2 to 4 acute GvHD in these patients
- To estimate the incidence of chronic GvHD and graft failure in these patients
- To estimate the incidence of non-hematologic peri-transplant regimen-related toxicity and regimen-related mortality in the first 100 days after transplantation in these patients
- To estimate the number of patients who require donor lymphocyte infusions and/or stem cell boosts after transplantation in this group of patients and evaluate its impact on immune reconstitution and engraftment
- To estimate the number of patients who develop evidence of EBV reactivation or post transplant lymphoproliferative disease (PTLPD) post transplant in this group of patients
- Describe the pharmacokinetics of rabbit anti-thymocyte globulin (rATG) in patients receiving allogeneic transplantation and determine the frequency of rATG antibody development
- Explore dose and patient characteristics as determinants of active rATG pharmacokinetic parameters
Originally this study began as a randomized comparison of two methods of stem cell selection utilizing the CliniMACS device. Both arms provided a purified product of CD34+ hematopoietic cells that was depleted of T-lymphocytes. One arm utilized a positive selection methodology using an anti-CD34 antibody and the other arm utilized negative selection with the anti-CD3 antibody OKT-3. There were no toxicities noted that would have required the study to be interrupted early, however, due to low accrual, it was decided to redesign the study. The new design focused on the standard arm utilizing negative selection, and all subsequent participants were treated in that manner. The patients who were treated on the positive selection arm are continuing to be monitored as specified in the original protocol, but will be reported in a descriptive manner only. The primary and secondary objectives of the current version of this study will be answered only by those patients receiving a haploidentical stem cell transplant utilizing a negative selection methodology.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Tennessee
-
Memphis, Tennessee, Stany Zjednoczone, 38105
- St. Jude Children's Research Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Lacking a HLA-identical sibling or unrelated donor matched at 6 HLA loci formally requested within an approximate 90 day period from search initiation and who has a mismatched family member donor available
At least 2 and less than or equal to 21 years of age
- Must have one of the following diagnosis:
- Acute lymphoid leukemia (ALL) in second, third, or subsequent remission.
- ALL in first remission but high risk for relapse.
- Acute myeloid leukemia (AML) in relapse or remission.
- Secondary AML / MDS
- Chronic myeloid leukemia (CML)
- Juvenile myelomonocytic leukemia (JMML).
- Myelodysplastic syndrome (MDS).
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Non-Hodgkin lymphoma in second or subsequent CR
- Patients with a shortening fraction ≥ 25%
- Patients with a creatinine clearance ≥ 40cc/min/1.73m^2
- Patients with FVC ≥ 40% of predicted or pulse oximetry ≥ 92% on room air
- Patients with direct bilirubin ≤ 3 mg/dL or SGPT ≤ 500 U/L
- Patients with a Karnofsky or Lansky (age dependent) performance score of ≥ 70
- Mismatched family member donor is available, HIV negative and ≥ 18 years of age
Exclusion Criteria:
- Patients who have received a previous hematopoietic stem cell allograft
- Patients with a known allergy to rabbit or murine products
- Patients with isolated CNS, testicular or other isolated extramedullary site of relapse
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Inny: 1
|
Infuzja komórek macierzystych pochodzących od członków rodziny niezgodnych HLA, przetworzonych za pomocą eksperymentalnego urządzenia Miltenyi Biotec CliniMACS.
A stem cell selection device.
Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3.
Rituximab was provided prior to transplant for PTLPD prophylaxis.
In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
To describe rate of hematopoietic and immune reconstitution in first 100 days posttransplant for pediatric patients with high-risk hematologic malignancies receiving haploidentical transplant processed with investigational CliniMACS cell sorting device.
Ramy czasowe: September 2005
|
September 2005
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Gregory A. Hale, M.D., St. Jude Children's Research Hospital
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu odpornościowego
- Nowotwory według typu histologicznego
- Zaburzenia limfoproliferacyjne
- Choroby limfatyczne
- Zaburzenia immunoproliferacyjne
- Nowotwory według lokalizacji
- Choroby Urologiczne
- Manifestacje urologiczne
- Choroby szpiku kostnego
- Choroby hematologiczne
- Zaburzenia mieloproliferacyjne
- Zaburzenia oddawania moczu
- Niedokrwistość
- Stany przedrakowe
- Choroby mielodysplastyczno-mieloproliferacyjne
- Białaczka, układ limfatyczny
- Białkomocz
- Anemia, hemoliza
- Chłoniak
- Nowotwory
- Zespoły mielodysplastyczne
- Nowotwory hematologiczne
- Białaczka
- Białaczka, mieloidalna
- Białaczka, szpikowa, ostra
- Chłoniak nieziarniczy
- Stan przedbiałaczkowy
- Białaczka, mielomonocytowa, młodzieńcza
- Prekursorowa komórkowa białaczka limfoblastyczna-chłoniak
- Białaczka, szpikowa, przewlekła, BCR-ABL dodatnia
- Hemoglobinuria
- Hemoglobinuria, napadowa
- Fizjologiczne skutki leków
- Czynniki immunologiczne
- Przeciwciała
Inne numery identyfikacyjne badania
- HAPSCT
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .